Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, have entered an option, research and license agreement worth up to $100 million. The partnership will leverage Dewpoint’s proprietary platform for biomolecular condensates and Bayer’s small molecule compound library to develop new treatments for cardiovascular and gynecological diseases.   Today, around 80 percent of the human proteome is still considered to be beyond the reach of smal...